<label id="zosxy"><s id="zosxy"><pre id="zosxy"></pre></s></label><label id="zosxy"><s id="zosxy"><wbr id="zosxy"></wbr></s></label>
<cite id="zosxy"><s id="zosxy"></s></cite>
        <cite id="zosxy"><del id="zosxy"></del></cite>

            INTRODUCTION
            Focus on two main therapeutics, Ophthalmology and Surgical arena of skin surface wounds, while selectively pursue therapeutics in Neurology, Oncology and Orthopaedics
            Essex Bio-Technology is a bio-pharmaceutical company that develops, manufactures and commercialises genetically engineered therapeutic rb-bFGF (FGF-2), having six commercialized biologics marketed in China since 1998.

            The products of the Company are principally prescribed for the treatment of wounds healing and diseases in Ophthalmology & Dermatology, which are marketed and sold through approximately 9000 hospitals and managed directly by its 43 regional sales offices in China.

            Leveraging on its in-house R&D platform in growth factor and antibody, the Company maintains a pipeline of projects in various clinical stages, covering a wide range of fields of indication.
            MILESTONES
            1990-2000
            R&D and Manufacturing
            1990
            R&D team established, started the research and development of rb-bFGF
            1996
            Established rb-bFGF API and preparation production plant
            1998
            1st rb-bFGF surgical product Beifuji launched in China
            1999
            1st rb-bFGF ophthalmic product Beifushu Eye Drops launched in China
            2001-2010
            Market Expansion
            2001
            Listed on GEM of HKEx
            2003
            Own sales network in China established
            2005
            2nd generation rb-bFGF products:Beifuxin Gel and Beifushu Eye Gel launched in China
            2006
            Beifushu became a well-known Rx ophthalmic brand in China and entered the forefront of China's ophthalmic prescription drug sales
            2010
            Company’s sales and distribution network enlarged to approximately 1,300 hospitals, managed directly by its 23 regional sales offices in China
            2011-now
            Accelerated Growth
            2011
            Listed on Main Board of HKEx ,stock code: 1061.HK
            2014
            Entered into the Import and Service Agreement with Pfizer
            2014
            New production plant put into operation
            2015
            Initiated Enrichment Programme to leverage external innovation
            2016
            Received a convertible loan of HK$150 million from the International Finance Corporation (IFC) of the World Bank Group
            2018
            Three single-dose eye drops obtained approval from NMPA for comercialisation
            2019
            First global clinical program (VISTA-1) initiated in U.S.
            2019
            3rd generation of rb-bFGF Eye Drops approved for commercialisation in China and entered National Major Scientific and Technological Special Project for“Significant New Drugs Development”
            2020
            The second production plant FUTURE ONE started construction
            2020
            First Overseas Research Centre: U.S Boston Centre opened
            2021
            Positive outcome of VISTA-2
            2021
            Preservative-free Unit-dose Moxifloxacin Hydrochloride Eye Drops Obtained Approval from NMPA for Commercilisation in China
            CONTACT US
            Head Office
            in Hong Kong
            Address
            Room 2818, China Merchants Tower, Shun Tak Centre, 168-200 Connaught Road Central, Hong Kong SAR, China
            Tel
            (852) 2587 7838
            Fax
            (852) 2587 7363
            Email
            essex@essexbio.com
            Map
            Headquarter
            in Zhuhai
            Address
            No.88, Keji 6th Road, Hi-Tech Zone, Zhuhai, Guangdong, China
            Tel
            (86) 756 3911188
            Fax
            (86) 756 3911185
            Map
            This website uses cookies to improve your overall experience. With your continued use, you are agreeing to accept our use of cookies.